The numbers arrived in late spring, and they didn't leave much room for interpretation. Between April 2024 and April 2025, American beekeepers watched 55.6% of their colonies die, according to an Auburn University survey—the steepest annual collapse since anyone started keeping count.
In agricultural circles, that figure hit hard. Perhaps harder than it should have, given how many seasons of declining bee health preceded it. Yet the losses still managed to shock, maybe because everyone knew what came next in the chain: roughly a third of global food crops depend on animal pollinators, and the insects shouldering that work keep disappearing.
Enter a cohort of startups convinced they've found the way through an impossibly narrow opening. Their pitch isn't another certified-organic label or a tweak to spray timing. It's precision engineered at the molecular level—biopesticides designed to obliterate crop pests while leaving bees, butterflies, and everything else untouched.
The approach represents a clean break from the broad-spectrum arsenal that's defined industrial agriculture for the better part of a century. Take Molagri, a Toronto outfit reportedly emerging from Y Combinator's accelerator program. The small team—just four people, according to founder Zaky Hassan—is building what he describes as an "insect receptor protein-binder discovery engine." It's a mouthful. Think of it as a distant cousin to CRISPR, though the underlying technology predates the gene-editing revolution and carries a less tangled regulatory path.
Honeybees aren't the only ones in play here. The biopesticides market reached $8.37 billion in 2025, according to Grand View Research, and a constellation of analyst projections puts it somewhere between $26 billion and $29 billion by 2032. That works out to compound annual growth around 15%—a trajectory driven less by hype than by the collision of tightening regulations and farmers running out of alternatives.
A Splintering Field
The biopesticide sector has fractured into competing technology camps, each chasing molecular specificity through different biochemical pathways.
GreenLight Biosciences, for instance, has commercialized double-stranded RNA molecules that slip into target pests and silence the genes keeping them alive. Vestaron deploys peptides engineered to latch onto ion channels found only in certain insects. A third cohort relies on synthetic pheromones that scramble mating behavior without disturbing anything else downwind.
What binds them together—aside from venture capital and a shared distaste for legacy chemistries—is regulatory momentum blowing in their favor. The EPA's Insecticide Strategy, finalized in April 2025, layered new mitigation requirements onto conventional pesticides, ostensibly to shield endangered species. The added compliance burden makes old-line chemicals costlier while cracking the door wider for targeted alternatives.
Europe got there first. The EU banned outdoor applications of three major neonicotinoids back in 2018, and member states have been ratcheting pollinator protections tighter ever since. The European Food Safety Authority released updated bee guidance in 2023, introducing risk-assessment frameworks that redefined what qualifies as genuinely "bee-safe." California and New York followed suit with state-level neonicotinoid restrictions kicking in during 2024, with phase-in schedules stretching toward 2027.
The regulatory ratchet, as they say, only turns one direction.
For a preview of rapid adoption, look to Brazil. The biocontrol market there hit R$4.35 billion during the 2024-25 growing season—an 18% jump year-over-year—and penetration in some major agricultural states pushed past 50% of planted acreage. Back in the U.S., retailers told CropLife in 2024 that biologicals were outpacing every other product category, though they also flagged persistent worries about inconsistent field performance and the knowledge gap among growers still learning how these products behave.
Converging Pressures
Three forces are colliding to pull agriculture away from broad-spectrum chemistries and toward molecularly precise biologics.
Start with the science itself. It's maturing, and the milestones are piling up. GreenLight's Calantha—ledprona, in the regulatory paperwork—became the first sprayable RNAi insecticide to earn EPA registration in December 2023. That approval cracked open a door that had been sealed for years, signaling to investors and agrochemical giants alike that RNA-based crop protection wasn't just a laboratory curiosity anymore.
